ORIGINAL RESEARCH article

Front. Immunol.

Sec. Inflammation

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1601690

This article is part of the Research TopicCommunity Series in the Role of Complement in Health and Disease: Volume IIView all 17 articles

Reduced hemolytic complement activity in the classical pathway (CH50) is a risk factor for poor clinical outcomes of patients with infections: A retrospective analysis of health insurance claims in

Provisionally accepted
Hiroyuki  KoamiHiroyuki Koami1*Yutaro  FurukawaYutaro Furukawa1Yuri  HirotaYuri Hirota1Akira  SasakiAkira Sasaki1Hirotaka  OgawaHirotaka Ogawa1Ayaka  MatsuokaAyaka Matsuoka1Kota  ShinadaKota Shinada1Kento  NakayamaKento Nakayama1Ryota  SakuraiRyota Sakurai1Sachiko  IwanagaSachiko Iwanaga1Takayuki  OnoharaTakayuki Onohara1Shogo  NarumiShogo Narumi1Mayuko  KobaMayuko Koba1Hirotaka  MoriHirotaka Mori2Yutaka  UmemuraYutaka Umemura3Kazuma  YamakawaKazuma Yamakawa4Kohji  OkamotoKohji Okamoto5Yuichiro  SakamotoYuichiro Sakamoto1
  • 1Saga University, Saga, Japan
  • 2Hokkaido University, Sapporo, Hokkaidō, Japan
  • 3Osaka General Medical Center, Osaka, Japan
  • 4Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
  • 5Kitakyushu Yahata Hospital, Kitakyushu, Fukuoka, Japan

The final, formatted version of the article will be published soon.

Purpose: To evaluate whether low CH50 (a comprehensive measure of hemolytic activity of the classical complement pathway) is associated with infection-related coagulopathy, organ dysfunction, and poor clinical outcomes.This was a retrospective study using Japanese health insurance claim data (2014)(2015)(2016)(2017)(2018)(2019)(2020)(2021)(2022)(2023). Adult patients whose CH50 values were measured within one week of admission were included. We divided the patients into three groups based on the normal CH50 range: Low CH50 (< 25 U/mL; n=168), Normal CH50 (25 ≤, < 48 U/mL; n=1273), and High CH50 (48 ≤ U/mL; n=1285).Results: Of 2,726 patients who met the inclusion criteria, logistic regression models demonstrated that decreased CH50 is a significant predictor of 180-day mortality (OR: 0.98-0.99). Cumulative survival rates in the Low CH50 group at 28 days and 180 days were both unfavorable (both p < 0.0001, Log-rank test).CH50 was significantly inversely correlated with SOFA, SIC, ISTH-overt DIC, and JAAM-2 DIC scores, and was also correlated with C3 and C4 levels. Diminished CH50 may be particularly useful in diagnosing SIC (specificity; 79.2%) and excluding ISTH-overt DIC (sensitivity; 90.5%). Moreover, patients with low levels of both CH50 and C3 had an extremely high mortality rate (25.0%).Low CH50 after infection is not only significantly associated with multiple organ failure and coagulopathy but is also an independent risk factor for poor prognosis. Complement activation after infection may help to avert organ damage and to improve clinical outcomes.

Keywords: CH50, Infection, Health insurance claims database, Outcome, coagulopathy

Received: 28 Mar 2025; Accepted: 20 May 2025.

Copyright: © 2025 Koami, Furukawa, Hirota, Sasaki, Ogawa, Matsuoka, Shinada, Nakayama, Sakurai, Iwanaga, Onohara, Narumi, Koba, Mori, Umemura, Yamakawa, Okamoto and Sakamoto. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Hiroyuki Koami, Saga University, Saga, Japan

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.